Navigation Links
New compound improves cognitive decline, symptoms of Alzheimer's disease in rodents
Date:1/12/2010

WINSTON-SALEM, N.C. A fast-acting compound that appears to improve cognitive function impairments in mice similar to those found in patients with progressive Alzheimer's disease has been identified by scientists at Wake Forest University School of Medicine and the Vanderbilt University Medical Center Program in Drug Discovery. Researchers hope to one day replicate the result in humans.

The compound benzylquinolone carboxylic acid (BQCA) has also been shown in previous rodent studies to lessen the occurrence and severity of the behavioral disturbances often symptomatic of Alzheimer's, such as hallucinations, delusions, paranoia and outbursts.

"That makes this compound somewhat novel," said Michelle M. Nicolle, Ph.D., an associate professor of gerontology at Wake Forest and co-researcher on the study, published recently in the Journal of Neuroscience. "We wanted to see if this very specific acting compound was able to change the way the brain works and whether or not it improved memory in our 'Alzheimer's mice,' which are experiencing progressive cognitive decline much like a person with Alzheimer's does."

Other attempts to identify such a specific treatment for Alzheimer's have failed, according to Nicolle.

"Current treatments only treat the symptoms while the underlying disease is still progressing," she said, "so recent research efforts are focusing on stopping disease progression instead of symptomatic treatment."

The researchers' findings suggest that the compound could alter the progression of disease in mice and, ultimately, hold importance for humans, as well.

BQCA activates a specific neurotransmitter receptor in the brain called the M1 muscarinic acetylcholine receptor. M1 receptors have been the focus of research into treatment of Alzheimer's disease because they affect the part of the brain that stimulates the memory and learning functions the disease inhibits. Until now, scientists have not found a treatment selective enough to activate the receptors without producing side effects such as nausea, vomiting and increased frequency of urination.

But in this study, Nicolle said, researchers found that BQCA boosted the weak signals of the M1 receptors in a mouse model of Alzheimer's disease.

"In Alzheimer's disease, the chemical signals the little bits of information that are talking to each other in the brain are reduced, so you can't do the tasks very well," Nicolle said. "BQCA is only boosting an existing signal, so it's really specific in its action."

BQCA also seemed to inhibit production of amyloid beta, one of the markers of Alzheimer's disease in the brain perhaps key to the compound's potential for slowing the progression of the disease.

Moreover, the compound works quickly, Nicolle explained. After just one administration of BQCA one hour before behavioral testing, mice were able to learn new ways to do tasks in this case, finding a piece of hidden peanut butter chip in one of two small flower pots that looked the same but smelled different. One of the pots was made to smell like lemon, indicating the location of a food reward, namely the peanut butter chip. The other pot smelled like clove, a smell that if followed, would lead the mouse to a pot with no food reward. All mice learned to locate the peanut butter chip in the pot that smelled like lemon.

However, when the odor stimuli were switched, making clove the indicator of the peanut butter and lemon the indicator of no reward, the BQCA-treated "Alzheimer's mice" were able to forget the old rule and quickly learn the new rule to locate the chip in the clove-scented pot. The untreated Alzheimer's mice had difficulty learning the new rule and persisted in looking for the chip in the lemon-scented pot a characteristic of impaired cognitive function known as "perseveration."

Tasks that require the replacement of old rules with new rules are categorized under the broad umbrella of cognition called "executive function" in humans. Examples of executive function such as planning, multitasking and activities of daily living, like cooking and getting dressed, are all capabilities that slip away as Alzheimer's disease progresses.

"In older people and in Alzheimer's disease patients, we call it flexible learning," Nicolle said. "They learn one rule, and they don't want to change the rule to get to the end goal."

Treatment with BQCA in mice allowed a previously learned rule to be replaced with a new one.

Because of the early indications that the compound could treat the behavioral symptoms associated with Alzheimer's, the researchers also believe BQCA could be targeted for treatment of schizophrenia. However, the compound will need further testing in the laboratory before it is ready for clinical trials with human participants.


'/>"/>

Contact: Jessica Guenzel
jguenzel@wfubmc.edu
336-716-3487
Wake Forest University Baptist Medical Center
Source:Eurekalert

Related medicine news :

1. Marijuana Compounds Could Beat Back Brain Cancer
2. Spice Compounds May Stem Tumor Growth
3. Coffee break: Compound brewing new research in colon, breast cancer
4. Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity
5. Texas State University Names Developer of ALKA-V6 Compound to Board of Advisors
6. Red-Grape Compound May Improve Diabetes
7. New Compound Shrinks Skin Cancers
8. CriticalPoint(TM) Launches Seven New Virtual Compounder(TM) Training Modules
9. NovaBay Pharmaceuticals to Present New Pre-Clinical Data on Lead Anti-Infective Compound for use in Onychomycosis at the 2009 IDSA Annual Meeting
10. Study shows how to boost value of Alzheimers-fighting compounds
11. Compound Targets, Destroys Cancer Stem Cells in Mice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... "FCPX editors can now reveal their media with growing colorful ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Color brings the ... can now reveal the media of their split screens with growing colorful panels. , ...
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are confused ... endometriosis. These women need a treatment plan to not only alleviate symptoms and ... help for preservation of fertility and ultimately achieving a pregnancy. The specialists at ...
(Date:6/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... the Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... , June 23, 2016 , ... on Thursday, July 7, 2016 , , , , LOCATION: ... , , , , EXPERT PANELISTS:  , , , ... Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and ... The global pharmaceutical industry is witnessing an exceptional era. ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... environments  Oticon , industry leaders in ... the launch of Oticon Opn ™, the world,s ... world of possibilities for IoT devices.      ... Opn, Oticon introduces a number of ,world firsts,: ...
Breaking Medicine Technology: